Aclarion, Inc. (ACONW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aclarion, Inc. (ACONW) trades at $0.03. Aclarion, Inc. is a healthcare technology company specializing in magnetic resonance spectroscopy (MRS) software. Their NOCISCAN-LS suite aids in the diagnosis of degenerative pain biomarkers. Market cap: $13,759, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for ACONW: ACONW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACONW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACONW: 1/1 perspectives are bearish.
Aclarion, Inc. (ACONW) Healthcare & Pipeline Overview
Aclarion, Inc. develops and markets the NOCISCAN-LS Post-Processor suite, a clinical decision support software utilizing magnetic resonance spectroscopy (MRS) to assist in the diagnosis of degenerative pain biomarkers. Operating within the healthcare information services sector, Aclarion aims to improve diagnostic accuracy and patient outcomes in pain management.
What Is the Investment Thesis for ACONW?
Aclarion, Inc. presents a speculative investment opportunity within the healthcare technology sector. The company's NOCISCAN-LS suite has the potential to improve the diagnosis and management of chronic lower back pain. Key value drivers include the adoption rate of NOCISCAN-LS by physicians and healthcare providers, the ability to secure favorable reimbursement policies from insurance companies, and the expansion of the product pipeline to address other chronic pain conditions. However, the company's negative profit margin of -10867.8% and small size (5 employees) present significant risks. Upcoming catalysts include potential partnerships, regulatory approvals, and commercialization milestones for NOCISCAN-LS.
Based on FMP financials and quantitative analysis
ACONW Key Highlights
- Aclarion operates in the healthcare information services sector, focusing on diagnostic solutions for chronic pain.
- The company's primary product is the NOCISCAN-LS Post-Processor suite, which includes NOCICALC-LS and NOCIGRAM-LS.
- Aclarion's NOCISCAN-LS suite utilizes magnetic resonance spectroscopy (MRS) to quantify levels of degenerative pain biomarkers.
- Aclarion's profit margin is -10867.8%, indicating significant losses.
- Aclarion's beta is 1.44, suggesting higher volatility compared to the market.
Who Are ACONW's Competitors?
Who Are ACONW's Competitors?
ACONW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HLTT Healthtech Solutions Inc. | $0.00 | +0.00% | 11K | 56 |
| HNGE Hinge Health, Inc. | $54.50 | +1.15% | 5B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.00 | +0.00% | $20.00M | 67 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FOXO FOXO Technologies Inc. | $0.00 | +0.00% | 3K | 63 |
| AMWL American Well Corporation (AMWL) | $7.80 | -1.39% | 131M | 52 |
| NH NantHealth, Inc. | $1.35 | +0.00% | 52 | |
| DOCS Doximity, Inc. | $21.40 | +1.57% | $4.00B | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACONW's Key Strengths?
- Proprietary MRS-based technology
- Clinical decision support software for pain management
- Potential to improve diagnostic accuracy and patient outcomes
What Are ACONW's Weaknesses?
- Limited financial resources (small market cap)
- Negative profit margin
- Small number of employees
What Could Drive ACONW Stock Higher?
- Potential partnerships with healthcare providers and research institutions to expand market reach and validate technology.
- Regulatory approvals for NOCISCAN-LS in new markets or for new applications.
- Publication of clinical studies demonstrating the efficacy and cost-effectiveness of NOCISCAN-LS.
- Securing favorable reimbursement policies from insurance companies to drive adoption of NOCISCAN-LS.
What Are the Key Risks for ACONW?
- Regulatory hurdles and delays in obtaining approvals for NOCISCAN-LS.
- Competition from established players in the pain management market with greater resources and market share.
- Technological obsolescence if competing technologies emerge that offer superior diagnostic capabilities.
- Limited financial resources may constrain the company's ability to invest in research and development, marketing, and sales.
- Unfavorable reimbursement policies from insurance companies could limit the adoption of NOCISCAN-LS.
What Are the Growth Opportunities for ACONW?
- Expansion into new geographic markets represents a significant growth opportunity for Aclarion. While currently focused on the United States, the company could explore international markets with similar healthcare needs and regulatory environments. This expansion could involve direct sales, partnerships with local distributors, or licensing agreements. The global market for pain management is substantial, offering a large addressable market for Aclarion's technology. Timeline: 2-3 years.
- Development of new applications for MRS technology beyond lower back pain could drive future growth. Aclarion could explore the use of MRS in diagnosing and managing other chronic pain conditions, such as neck pain, arthritis, and neuropathic pain. This would involve expanding the NOCISCAN-LS suite to include new biomarkers and clinical decision support tools. The market for these additional applications could be substantial. Timeline: 3-5 years.
- Securing favorable reimbursement policies from insurance companies is crucial for driving adoption of NOCISCAN-LS. Aclarion needs to demonstrate the clinical and economic value of its technology to payers to ensure that it is covered under insurance plans. This would involve conducting clinical trials, publishing peer-reviewed studies, and engaging with payers to negotiate reimbursement rates. Successful reimbursement could significantly increase the adoption of NOCISCAN-LS. Timeline: Ongoing.
- Strategic partnerships with healthcare providers and research institutions could accelerate the adoption and validation of Aclarion's technology. Collaborating with leading pain clinics, hospitals, and universities would provide access to patients, data, and expertise. These partnerships could also facilitate clinical trials, product development, and marketing efforts. Timeline: Ongoing.
- Leveraging artificial intelligence (AI) and machine learning (ML) to enhance the capabilities of NOCISCAN-LS could provide a competitive advantage. Aclarion could use AI/ML to improve the accuracy and efficiency of biomarker analysis, personalize treatment recommendations, and predict patient outcomes. This would involve integrating AI/ML algorithms into the NOCISCAN-LS software platform. Timeline: 2-3 years.
What Opportunities Does ACONW Have?
- Expansion into new geographic markets
- Development of new applications for MRS technology
- Strategic partnerships with healthcare providers
What Threats Does ACONW Face?
- Regulatory hurdles and reimbursement pressures
- Competition from established players in the pain management market
- Technological obsolescence
What Are ACONW's Competitive Advantages?
- Proprietary technology: Aclarion's MRS-based technology and clinical decision support software may be protected by patents or trade secrets.
- Data assets: The company's database of MRS data and clinical outcomes could provide a competitive advantage.
- Expertise: Aclarion's team of scientists and engineers may possess specialized knowledge and expertise in MRS and pain management.
What Does ACONW Do?
Aclarion, Inc., founded in 2008 and formerly known as Nocimed, Inc., is a healthcare technology company focused on developing and commercializing innovative diagnostic solutions for chronic pain. The company's core technology centers around magnetic resonance spectroscopy (MRS), a non-invasive imaging technique that provides detailed biochemical information about tissue composition. Aclarion's primary product is the NOCISCAN-LS Post-Processor suite, which includes NOCICALC-LS and NOCIGRAM-LS. NOCICALC-LS processes data acquired from disc MRS to quantify levels of degenerative pain biomarkers. NOCIGRAM-LS then utilizes this data to provide clinical decision support to physicians. Aclarion's solutions are designed to improve the accuracy and efficiency of diagnosing and managing chronic lower back pain, a significant unmet need in the healthcare industry. The company is based in Broomfield, Colorado, and targets the United States market.
What Products and Services Does ACONW Offer?
- Develops software applications for magnetic resonance spectroscopy (MRS).
- Offers NOCISCAN-LS Post-Processor suite.
- NOCICALC-LS processes disc MRS data to calculate levels of degenerative pain biomarkers.
- NOCIGRAM-LS is a clinical decision support software.
- Aids in the diagnosis and management of chronic lower back pain.
- Provides tools for physicians to improve diagnostic accuracy.
How Does ACONW Make Money?
- Software licensing: Aclarion likely generates revenue through licensing its NOCISCAN-LS software suite to hospitals, clinics, and other healthcare providers.
- Data processing fees: The company may charge fees for processing MRS data using its NOCICALC-LS software.
- Clinical decision support services: Aclarion could offer clinical decision support services based on the output of its NOCIGRAM-LS software.
What Industry Does ACONW Operate In?
Aclarion operates within the healthcare information services industry, which is experiencing growth driven by the increasing demand for data-driven diagnostic and treatment solutions. The market for chronic pain management is substantial, with a significant portion of the population affected by conditions like lower back pain. The competitive landscape includes companies offering various diagnostic and therapeutic approaches for pain management. Aclarion aims to differentiate itself through its MRS-based technology and clinical decision support software. The industry is subject to regulatory oversight and reimbursement pressures, which can impact the adoption of new technologies.
Who Are ACONW's Key Customers?
- Hospitals and medical centers
- Pain clinics and specialists
- Radiology centers
ACONW Financials
ACONW Latest News
No recent news available for ACONW.
ACONW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACONW.
Price Targets
Wall Street price target analysis for ACONW.
ACONW MoonshotScore
What does this score mean?
The MoonshotScore rates ACONW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Brent Ness
CEO
Information on Brent Ness's background is not available in the provided context. His career history, education, and previous roles are unknown. Further research would be required to provide a comprehensive biography.
Track Record: Information on Brent Ness's track record is not available in the provided context. Key achievements, strategic decisions, and company milestones under his leadership are unknown. Further research would be required to assess his performance as CEO.
Common Questions About ACONW (Healthcare)
What does Aclarion, Inc. do?
Aclarion, Inc. is a healthcare technology company focused on developing and commercializing diagnostic solutions for chronic pain, particularly lower back pain. Its core product, the NOCISCAN-LS Post-Processor suite, utilizes magnetic resonance spectroscopy (MRS) to quantify levels of degenerative pain biomarkers and provide clinical decision support to physicians. The company aims to improve the accuracy and efficiency of diagnosing and managing chronic lower back pain, addressing a significant unmet need in the healthcare industry.
What do analysts say about ACONW stock?
AI analysis is currently pending for ACONW, so an analyst consensus is not yet available. Key valuation metrics to consider include the company's market capitalization, revenue growth, and profitability. Growth considerations include the adoption rate of NOCISCAN-LS, the ability to secure favorable reimbursement policies, and the expansion of the product pipeline. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
What are the main risks for ACONW?
Aclarion faces several risks, including regulatory hurdles and reimbursement pressures, competition from established players in the pain management market, and the potential for technological obsolescence. The company's limited financial resources may also constrain its ability to invest in research and development, marketing, and sales. Additionally, unfavorable reimbursement policies from insurance companies could limit the adoption of NOCISCAN-LS. These risks should be carefully considered by investors.
What are the key factors to evaluate for ACONW?
Evaluating ACONW involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Proprietary MRS-based technology. Primary risk to monitor: Regulatory hurdles and delays in obtaining approvals for NOCISCAN-LS. This is not financial advice.
How frequently does ACONW data refresh on this page?
ACONW prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ACONW's recent stock price performance?
Recent price movement in Aclarion, Inc. (ACONW) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary MRS-based technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ACONW overvalued or undervalued right now?
Determining whether Aclarion, Inc. (ACONW) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ACONW?
Before investing in Aclarion, Inc. (ACONW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- AI analysis pending.